Structural leitmotif and functional variations of the structural catalytic core in (chymo)trypsin-like serine/cysteine fold proteinases. 2021

Alexander I Denesyuk, and Sergei E Permyakov, and Mark S Johnson, and Eugene A Permyakov, and Vladimir N Uversky, and Konstantin Denessiouk
Institute for Biological Instrumentation of the Russian Academy of Sciences, Federal Research Center "Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences", Pushchino, Moscow region 142290, Russia; Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, Turku 20520, Finland. Electronic address: adenesyu@abo.fi.

Proteinases with the (chymo)trypsin-like serine/cysteine fold comprise a large superfamily performing their function through the Acid - Base - Nucleophile catalytic triad. In our previous work (Denesyuk AI, Johnson MS, Salo-Ahen OMH, Uversky VN, Denessiouk K. Int J Biol Macromol. 2020;153:399-411), we described a universal three-dimensional (3D) structural motif, NBCZone, that contains eleven amino acids: dipeptide 42 T-43 T, pentapeptide 54 T-55 T-56 T-57 T(base)-58 T, tripeptide 195 T(nucleophile)-196 T-197 T and residue 213 T (T - numeration of amino acids in trypsin). The comparison of the NBCZones among the members of the (chymo)trypsin-like protease family suggested the existence of 15 distinct groups. Within each group, the NBCZones incorporate an identical set of conserved interactions and bonds. In the present work, the structural environment of the catalytic acid at the position 102 T and the fourth member of the "catalytic tetrad" at the position 214 T was analyzed in 169 3D structures of proteinases with the (chymo)trypsin-like serine/cysteine fold. We have identified a complete Structural Catalytic Core (SCC) consisting of two classes and four groups. The proteinases belonging to different classes and groups differ from each other by the nature of the interaction between their N- and C-terminal β-barrels. Comparative analysis of the 3CLpro(s) from SARS-CoV-2 and SARS-CoV, used as an example, showed that the amino acids at positions 103 T and 179 T affect the nature of the interaction of the "catalytic acid" core (102 T-Core, N-terminal β-barrel) with the "supplementary" core (S-Core, C-terminal β-barrel), which ultimately results in the modulation of the enzymatic activity. The reported analysis represents an important standalone contribution to the analysis and systematization of the 3D structures of (chymo)trypsin-like serine/cysteine fold proteinases. The use of the developed approach for the comparison of 3D structures will allow, in the event of the appearance of new representatives of a given fold in the PDB, to quickly determine their structural homologues with the identification of possible differences.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D002384 Catalysis The facilitation of a chemical reaction by material (catalyst) that is not consumed by the reaction. Catalyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D012697 Serine Endopeptidases Any member of the group of ENDOPEPTIDASES containing at the active site a serine residue involved in catalysis. Serine Endopeptidase,Endopeptidase, Serine,Endopeptidases, Serine
D014357 Trypsin A serine endopeptidase that is formed from TRYPSINOGEN in the pancreas. It is converted into its active form by ENTEROPEPTIDASE in the small intestine. It catalyzes hydrolysis of the carboxyl group of either arginine or lysine. EC 3.4.21.4. Tripcellim,Trypure,beta-Trypsin,beta Trypsin
D045473 Severe acute respiratory syndrome-related coronavirus A species of CORONAVIRUS causing atypical respiratory disease (SEVERE ACUTE RESPIRATORY SYNDROME) in humans. The organism is believed to have first emerged in Guangdong Province, China, in 2002. The natural host is the Chinese horseshoe bat, RHINOLOPHUS sinicus. HCoV-SARS,SARS Virus,SARS-Associated Coronavirus,SARS-CoV,SARS-CoV-1,SARS-like coronavirus,SARSr-CoV,SARSrCoV,Sarbecovirus,Severe Acute Respiratory Syndrome Virus,Severe acute respiratory syndrome coronavirus,SARS Coronavirus,SARS-Related Coronavirus,Urbani SARS-Associated Coronavirus,Coronavirus, SARS,Coronavirus, SARS-Associated,Coronavirus, SARS-Related,Coronavirus, Urbani SARS-Associated,SARS Associated Coronavirus,SARS Related Coronavirus,SARS like coronavirus,SARS-Associated Coronavirus, Urbani,SARS-like coronaviruses,SARSrCoVs,Sarbecoviruses,Severe acute respiratory syndrome related coronavirus,Urbani SARS Associated Coronavirus

Related Publications

Alexander I Denesyuk, and Sergei E Permyakov, and Mark S Johnson, and Eugene A Permyakov, and Vladimir N Uversky, and Konstantin Denessiouk
May 1994, Nature,
Alexander I Denesyuk, and Sergei E Permyakov, and Mark S Johnson, and Eugene A Permyakov, and Vladimir N Uversky, and Konstantin Denessiouk
June 2020, International journal of biological macromolecules,
Alexander I Denesyuk, and Sergei E Permyakov, and Mark S Johnson, and Eugene A Permyakov, and Vladimir N Uversky, and Konstantin Denessiouk
November 1988, Proceedings of the National Academy of Sciences of the United States of America,
Alexander I Denesyuk, and Sergei E Permyakov, and Mark S Johnson, and Eugene A Permyakov, and Vladimir N Uversky, and Konstantin Denessiouk
February 1982, The Biochemical journal,
Alexander I Denesyuk, and Sergei E Permyakov, and Mark S Johnson, and Eugene A Permyakov, and Vladimir N Uversky, and Konstantin Denessiouk
January 1997, Biological chemistry,
Alexander I Denesyuk, and Sergei E Permyakov, and Mark S Johnson, and Eugene A Permyakov, and Vladimir N Uversky, and Konstantin Denessiouk
February 1982, The Biochemical journal,
Alexander I Denesyuk, and Sergei E Permyakov, and Mark S Johnson, and Eugene A Permyakov, and Vladimir N Uversky, and Konstantin Denessiouk
April 1993, Thrombosis research,
Alexander I Denesyuk, and Sergei E Permyakov, and Mark S Johnson, and Eugene A Permyakov, and Vladimir N Uversky, and Konstantin Denessiouk
June 1984, Thrombosis research,
Alexander I Denesyuk, and Sergei E Permyakov, and Mark S Johnson, and Eugene A Permyakov, and Vladimir N Uversky, and Konstantin Denessiouk
March 1986, Biological chemistry Hoppe-Seyler,
Alexander I Denesyuk, and Sergei E Permyakov, and Mark S Johnson, and Eugene A Permyakov, and Vladimir N Uversky, and Konstantin Denessiouk
July 2004, Genomics,
Copied contents to your clipboard!